Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation

Table 1 gastrointestinal toxicity profile of fluoropyrimidine based chemotherapy used in colorectal cancer

Regimen	Patient setting	CID overall	CID grade 3/4	Oral mucositis overall	Oral mucositis grade 3/4	Ref.
Flouropyrimidine monotherapy
5-FU/LV bolus	Adjuvant	79%	21%-30%	28%	1%-8.1%	[93]
5-FU/LV infusion	Adjuvant	-	4%	-	2%	[9]
Capecitabine oral	Adjuvant	46%	11%	22%	2%	[10]
Combation therapy with Oxaliplatin/Irinotecan
FLOX	Adjuvant	-	38%	-	-	[16]
FOLFOX	Adjuvant	56.3%	10.8%	41.6%	2.7%	[94]
XELOX	Adjuvant	60%	19%	21%	< 1%	[95]
FOLFOX	Advanced CRC	46%	5%	30%	1%	[96]
XELOX	Advanced CRC	50%	14%	28%	2%	[17]
FOLFIRI	Advanced CRC	63%	10%	35%	1%	[96]
XELIRI	Advanced CRC	-	47.5%	-	-	[15]

CID: Chemotherapy-induced diarrhea; CRC: Colorectal cancer; 5-FU/LV: Intravenous 5-fluorouracil and leucovorin; FLOX: Bolus 5-FU and oxaliplatin; FOLFOX: Infusional 5-FU and oxaliplatin; XELOX: Oral capecitabine and oxaliplatin; FOLFIRI: Infusional 5-FU and irinotecan; XELIRI: Oral capecitabine and irinotecan.